A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study

Trial Profile

A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Anagrelide; Interferon alpha; Peginterferon alfa
  • Indications Essential thrombocythaemia
  • Focus Therapeutic Use
  • Acronyms RUXBETA
  • Most Recent Events

    • 16 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 17 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top